DURHAM, N.C., Aug. 3, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the Company now offers its revolutionary anti-aging, anti-wrinkle skin care cream, DERMACYTE® Oxygen Concentrate, in an elegant, easy-to-use 10ml pump bottle. Beginning August 9th, retail orders for the 10ml pump can be placed on the Company's secure website at www.BuyDermacyte.com.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7802
"Our new packaging is in direct response to what our customers prefer," said Maria Isabel Tamargo, Assistant Vice President of Sales and Marketing. "It is an easy-to-use airless pump that provides many more applications than the first generation package. As importantly, it allows you to apply what you need and store the rest, thereby offering users more control over the amount of DERMACYTE Concentrate used per application."
DERMACYTE Oxygen Concentrate is a scientifically designed, proprietary cream made to enhance oxygen delivery to skin. It is the first product in a broad and diverse cosmetic line currently under development by Oxygen Biotherapeutics. It complements the newly introduced DERMACYTE Oxygenating Eye Complex, which has several ingredients that target the eye contour area. The DERMACYTE skin care line uses our oxycyte technology (an oxygen carrier) to deliver oxygen to tissues, such as skin.
Skin Benefits of Oxygen
Oxygen is essential for radiant, young-looking skin. It assists in the production of collagen and elastin, as well as with skin repair and regeneration. As we age, the body's ability to deliver oxygen to dermal tissue deteriorates. A lack of oxygen at the cellular level can cause skin to age prematurely, increasing the appearance of fine lines and age spots, making skin look dry and dull. A boost in oxygen may enhance the overall appearance and feel of your skin, leaving it smoother and healthier-looking.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The Company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte® that is being formulated for both intravenous and topical delivery for conditions including but not limited to traumatic brain injury, decompression sickness and topical wounds. This same PFC is included in the Company's full line of personal skin care products. More information is available at www.oxybiomed.com.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
The DERMACYTE logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7792
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the plans for the expansion of the DERMACYTE product line and the timing of the introduction of those new products. Matters beyond the company's control could lead to delays in the new product introductions and customer acceptance of these new products. Furthermore, there can be no assurance that such plans will lead to meaningful sales of DERMACYTE or generate any revenue for the company. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
